PPTA Statement on the Urgent Need for Plasma Donation

COVID-19 continues to present a prolonged, global public health emergency, but PPTA remains steadfastly committed to its mission to promote the availability of — and access to — safe and effective plasma protein therapies for all patients. PPTA member companies operate more than 1,000 Source plasma donation centers in the U.S. and four countries in the European Union and manufacture plasma-derived therapies that treat patients with serious, rare, and often genetic diseases and disorders, including: primary immune deficiencies, bleeding disorders, Alpha-1 Antitrypsin deficiency, hereditary angioedema, and certain neurological conditions. These conditions are often only treated with therapies produced from plasma.

There is an urgent need for plasma donations.

- From PPTA Statement

Read More

back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo